Dr. Jeremy Caplin Joins PetVivo Holdings, Inc. as the Director of Research
June 27 2023 - 8:00AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company")
an emerging biomedical device company focused on the
commercialization of innovative medical devices and therapeutics
for companion animals and animal athletes is pleased to announce
that Dr. Jeremy Caplin has accepted a position with the Company as
its new Research Director.
"Jeremy is a key addition to our research and
development team,” said John Lai, Chief Executive Officer of
PetVivo Holdings, Inc. “Jeremy’s prior experiences with other world
renown laboratories and biomaterial research institutions provides
us an innovative expert to better understand, develop and apply our
proprietary protein-based biomaterials.”
Dr. Caplin received his PhD degree in
bioengineering at Georgia Institute of Technology, where he
developed a hydrogel platform as an implantable biomaterial for
local and sustained drug delivery to treat orthopedic hardware
infections for various bone injuries and defects in both small and
large animal models. He has extensive experience in areas such as:
the synthesis and development of various biomaterial platforms,
including hydrogels, PLGA nanoparticles, and liposomes; and
translating the developed platform to preclinical studies through
the development of animal models as the lead surgeon. Through this
work, Dr. Caplin collaborated on an ovine ulnar osteotomy model for
infection clearance and bone regeneration with the Department of
Large Animal Medicine at UGA, phage microparticles and lysostaphin
treatment of wound infections with the Naval Medical Research
Center, and cystic fibrosis treatment utilizing phage
microparticles at the Emory Antibiotic Resistance Center. Prior to
his Ph.D. work, he obtained his Master’s degree in mechanical
engineering from Iowa State University. While at Iowa State, his
focus was in thermofluid sciences and his thesis work was in the
field of organ-on-a-chip technology. Between Dr. Caplin’s Master’s
and PhD programs, he joined the Langer Lab at MIT as a research
technician. This research project was a collaboration between
Professors Robert Langer, Dan Anderson, and Phil Sharp to create a
high throughput microfluidic device for single-cell microRNA
sequencing. He also was selected for the NSF EAPSI fellowship to
collaborate with labs at Seoul National University and was also
selected for the Lush Young Researcher Prize, which recognizes work
done in researching alternatives to animal testing, wherein he was
selected among 13 finalists from around the world. Most recently,
he was nominated by Georgia Tech to participate in the Global Young
Scientists Summit in Singapore, to engage with top scientific minds
from across the world. Dr. Caplin also holds a Bachelor’s degree in
Physics from Gustavus Adolphus College in St. Peter, Minnesota.
“I am incredibly excited to join the PetVivo
manufacturing, research and development team to contribute to
development and commercialization of its life changing veterinary
medical devices, including Spryng™ with OsteoCushion™ Technology,”
said Dr. Caplin. “I truly believe PetVivo’s platform technology has
the ability to improve the medical outcome of humans and animals
that suffer from one or more debilitating afflictions, thereby
enhancing their lives.”
For more information about PetVivo Holdings,
Inc. and its innovative product, Spryng, please contact
info1@petvivo.com or visit https://petvivo.com/ and
https://sprynghealth.com/.
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint related afflictions,
including osteoarthritis, in dogs and horses, is currently
available for commercial sale to veterinarians.
CONTACT:John Lai, CEOPetVivo Holdings,
Inc.Email: info1@petvivo.com(952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the potential listing of the Company’s common stock on
Nasdaq, are based on information currently available the Company
and its current plans or expectations and are subject to a number
of uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2022 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jun 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024